Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 14/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188905 | 0.82 | HTR2A (0.42) | HTR2AHRH1 | |
| SCHEMBL31572076 | 0.82 | AOC3 (0.58) | HTR2AHRH1 | |
| SCHEMBL5454333 | 0.82 | AOC3 (0.58) | UTS2RHTR2AHRH1 | |
| SCHEMBL4731821 | 0.82 | HTR2A (0.42) | HTR2AHRH1 | |
| SCHEMBL6829520 | 0.82 | AOC3 (0.58) | HTR2AHRH1 | |
| SCHEMBL4733883 | 0.82 | CHRM2 (0.49) | UTS2RHTR2AHRH1 | |
| SCHEMBL19399104 | 0.82 | ALOX5 (0.41) | UTS2RCHRNA7 | |
| SCHEMBL19399116 | 0.82 | ALOX5 (0.41) | UTS2RCHRNA7 | |
| SCHEMBL1534201 | 0.82 | HTR2A (0.67) | HTR2AHRH1 | |
| SCHEMBL1534343 | 0.82 | HTR2A (0.67) | HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043104-A1 | UII-modulating compounds and their use | ACADIA PHARMACEUTICALS INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2006135694-A2 | UII-MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2004043921-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES. | NATCO PHARMA LIMITED (IN) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043104-A1 | UII-modulating compounds and their use | UTS2R, GPR17, GPR119 | UTS2R 1/4885HTR2A 169/4885HRH1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.